Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. [electronic resource]
Producer: 20190514Description: 2029-2036 p. digitalISSN:- 1440-1746
- Adult
- Antiviral Agents -- adverse effects
- Carbamates -- adverse effects
- Computer Simulation
- Cost-Benefit Analysis
- Drug Combinations
- Drug Costs
- Drugs, Generic -- adverse effects
- Female
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C -- diagnosis
- Heterocyclic Compounds, 4 or More Rings -- adverse effects
- Humans
- India
- Male
- Models, Economic
- Quality of Life
- Quality-Adjusted Life Years
- Sofosbuvir -- adverse effects
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.